Tweet
Shire PLC (NASDAQ:SHPG) â€“ Stock analysts at SunTrust Banks cut their FY2020 earnings estimates for shares of Shire in a research note issued to investors on Tuesday, August 14th. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will earn $17.31 per share for the year, down from their prior forecast of $17.61. SunTrust Banks also issued estimates for Shire's FY2021 earnings at $18.85 EPS and FY2022 earnings at $20.35 EPS. Get Shire alerts:
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 EPS for the quarter, topping analysts' consensus estimates of $3.67 by $0.21. The company had revenue of $3.92 billion for the quarter. Shire had a net margin of 31.06% and a return on equity of 13.22%. Shire's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.73 EPS. A number of other brokerages have also commented on SHPG. Kepler Capital Markets reiterated a "buy" rating on shares of Shire in a report on Friday, May 11th. BidaskClub lowered shares of Shire from a "hold" rating to a "sell" rating in a report on Thursday. BTIG Research reiterated a "buy" rating and set a $195.00 price target on shares of Shire in a report on Sunday, April 29th. Royal Bank of Canada set a $186.00 price target on shares of Shire and gave the stock a "buy" rating in a report on Sunday, April 22nd. Finally, Zacks Investment Research upgraded shares of Shire from a "sell" rating to a "hold" rating in a report on Monday, April 23rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of "Buy" and an average target price of $201.18.
Shares of NASDAQ:SHPG opened at $171.50 on Thursday. The firm has a market cap of $52.16 billion, a PE ratio of 11.32, a price-to-earnings-growth ratio of 1.52 and a beta of 1.19. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.45. Shire has a 52 week low of $123.73 and a 52 week high of $177.51.
A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its holdings in Shire by 2.8% in the second quarter. Legal & General Group Plc now owns 11,510 shares of the biopharmaceutical company's stock valued at $1,943,000 after buying an additional 317 shares during the period. Signaturefd LLC lifted its holdings in Shire by 18.4% in the first quarter. Signaturefd LLC now owns 2,165 shares of the biopharmaceutical company's stock valued at $323,000 after buying an additional 336 shares during the period. Azimuth Capital Management LLC lifted its holdings in Shire by 3.1% in the second quarter. Azimuth Capital Management LLC now owns 12,044 shares of the biopharmaceutical company's stock valued at $2,033,000 after buying an additional 360 shares during the period. United Capital Financial Advisers LLC lifted its holdings in Shire by 7.2% in the first quarter. United Capital Financial Advisers LLC now owns 5,946 shares of the biopharmaceutical company's stock valued at $888,000 after buying an additional 401 shares during the period. Finally, Usca Ria LLC lifted its holdings in Shire by 2.4% in the first quarter. Usca Ria LLC now owns 19,828 shares of the biopharmaceutical company's stock valued at $2,962,000 after buying an additional 467 shares during the period. Institutional investors and hedge funds own 17.61% of the company's stock.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology